Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent reform saga opens in Senate

Executive Summary

Work on patent reform legislation begins in the Senate June 6 with hearings by the full Judiciary Committee. Although crafted by a bipartisan group of leaders from the House and Senate Judiciary Committees, the bill remains a work in progress (1"The Pink Sheet" April 23, 2007, p. 8). Provisions limiting damage awards for patent infringement and lengthening the time frame for patent challenges remain open issues. A procedural maneuver kept the original bill intact when it moved out of the Courts, Internet and Intellectual Property Subcommittee in May, and subcommittee chairman Rep. Howard Berman, D-Calif., has pledged to reach a compromise to facilitate passage of the legislation this year (2"The Pink Sheet" May 21, 2007, p. 13)...

You may also be interested in...



PTO Says Patent Damages Should Be Left To Courts, Not Congress

Rep. Howard Berman, D-Calif., has moved patent reform legislation to the House Judiciary Committee but has not yet hammered out a compromise on the measure's damage provisions

Patent Reform Bill Gets Cool Reception From Rx Industry; Damage Cap Is Worry

A new patent reform bill introduced in Congress is likely to undergo revisions in the face of criticism from the pharmaceutical industry

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

UsernamePublicRestriction

Register

PS048432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel